Contribution of Components of Metabolic Syndrome to Cognitive Performance in Middle-Aged Adults

Abstract

Introduction Metabolic syndrome (MetS) has been associated with impaired cognition in different cognitive domains. This study investigated the association between MetS and cognitive functioning in middle-aged Bulgarians across different definitions of MetS severity. Material and Methods Our cross-sectional sample included 112 participants (67 free of MetS and 45 with MetS) with a mean age of 50.04 ± 3.31 years. The following MetS variables were considered—presence of MetS, continuously measured MetS components, dichotomized MetS components, number of MetS components present, and Metabolic Syndrome Severity Score (MSSS). Participants’ cognitive performance was assessed using the Consortium to Establish a Registry for Alzheimer’s Disease Neuropsychological Battery (CERAD-NB). We employed multivariate regression models to investigate the associations between different measures of MetS severity and CERAD-NB total and subtest scores. Results Bivariate analyses showed that the CERAD-NB total score was significantly higher in women, participants with a university degree, those with normal blood pressure, normal waist circumference, and low triglyceride levels, compared with their counterparts. MetS participants had lower CERAD-NB total score (78.87 ± 6.89 vs. 84.97 ± 7.84) and specifically performed poorer on the subtest Word List Recall (7.16 ± 1.52 vs. 7.99 ± 1.52). These findings persisted after controlling for age, gender, and education. Next, generalized linear regression indicated that the CERAD-NB total score was lower in participants with MetS (β = −4.86; 95% confidence interval [CI]: −7.60, −2.11), those with more MetS components (β = −8.31; 95% CI: −14.13, −2.50 for fours vs. 0 components) and with an increase in MSSS (β = −3.19; 95% CI: −4.67, −1.71). Hypertension independently contributed to lower CERAD-NB total score (β = −4.00; 95% CI: −6.81, −1.19). Conclusions Across several definitions, MetS was associated with lower cognitive functioning, and MetS severity appeared to be a better predictor than most MetS components. Recognizing and reducing severity of MetS components might be helpful in supporting cognitive functioning. Further longitudinal research is needed to shed more light on the relationship between MetS and cognitive functioning across the life span.

Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis

“…Although CERAD originally examined cognitive deficits commonly seen in Alzheimer's disease, such as memory impairment, disorientation, loss of expressive and receptive language, and dyspraxia ( 21 ), by adding the PLUS subtests the domains can be expanded so that the CERAD Plus batterie also appears suitable for assessing cognitive deficits of other causes. The CERAD Plus has been used for cognitive assessments in other degenerative diseases like Parkinson's disease ( 32 , 33 ), inflammatory diseases like Neuro-Sjögren's syndrome ( 34 ), in patients with microbleeds after stroke ( 35 ), or middle-aged adults with metabolic syndrome with total score ( 36 ) underlining its broad applicability.…”

Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction

“…For instance, metabolic syndrome is significantly associated with cognitive impairment in persons with schizophrenia [301]. Persons with metabolic syndrome perform considerably worse at cognitive performance tasks compared with those with no metabolic syndrome [302]. Metabolic syndrome was associated with a higher risk for cognitive impairment that was observed across several studies.…”

Natural Aporphine Alkaloids with Potential to Impact Metabolic Syndrome

“…Alzheimer’s disease (AD) is the most common cause of senile dementia worldwide, characterized by both cognitive and behavioral deficit. Evidence has shown that metabolic syndrome drives blood-brain barrier impairment with neuroinflammation development paralleled by the accumulation of toxic amyloid, causing cognition impairment in different cognitive domains [ 65 , 66 ]. Aβ oligomers (AβO) are responsible for several pathological mechanisms during the development of AD, including abnormality of cellular homeostasis and synaptic function, inevitably leading to cell death.…”